General description
Our SAFC® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity Program.
M-Clarity Program
Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.
To request the documentation for this product, please contact Customer Support and select ‘Product Documentation′. Please note that access to documentation for this product requires a confidentiality disclosure agreement.
Biochem/physiol Actions
The enzymatic activities of butyrylcholinesterase (BChE) and paraoxonase 1 (PON1), two serum enzymes synthesized by the liver and related with inflammation, were decreased in a sepsis animal model injected with LPS. Choline chloride administered intravenously at 20 mg/kg body weight prevents the LPS-mediated decreases in the activities of these two enzymes .
Substrates
Choline acetyltransferase substrate
Legal Information
SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 41116107
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- MPN:
- PHG0021-100G
- CAS:
- 67-48-1
